BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nathan SD, King CS. Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther 2014;8:875-85. [PMID: 25061279 DOI: 10.2147/DDDT.S64907] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Liu H, Li Y, Zou Y, Zhang X, Shi X, Yin Z, Lin Y. Influence of miRNA-30a-5p on Pulmonary Fibrosis in Mice with Streptococcus pneumoniae Infection through Regulation of Autophagy by Beclin-1. Biomed Res Int 2021;2021:9963700. [PMID: 34604389 DOI: 10.1155/2021/9963700] [Reference Citation Analysis]
2 Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res 2018;19:32. [PMID: 29471816 DOI: 10.1186/s12931-018-0730-2] [Cited by in Crossref: 130] [Cited by in F6Publishing: 115] [Article Influence: 32.5] [Reference Citation Analysis]
3 Nakamura Y, Suda T. Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med 2015;9:163-71. [PMID: 27625576 DOI: 10.4137/CCRPM.S39897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Chen NY, D Collum S, Luo F, Weng T, Le TT, M Hernandez A, Philip K, Molina JG, Garcia-Morales LJ, Cao Y, Ko TC, Amione-Guerra J, Al-Jabbari O, Bunge RR, Youker K, Bruckner BA, Hamid R, Davies J, Sinha N, Karmouty-Quintana H. Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2016;311:L238-54. [PMID: 27317687 DOI: 10.1152/ajplung.00142.2016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
5 Agassandian M, Tedrow JR, Sembrat J, Kass DJ, Zhang Y, Goncharova EA, Kaminski N, Mallampalli RK, Vuga LJ. VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis. Cell Signal 2015;27:2467-73. [PMID: 26386411 DOI: 10.1016/j.cellsig.2015.09.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
6 Ji X, Wu B, Fan J, Han R, Luo C, Wang T, Yang J, Han L, Zhu B, Wei D, Chen J, Ni C. The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis. Sci Rep 2015;5:14131. [PMID: 26370615 DOI: 10.1038/srep14131] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
7 Zhang JT, Chen KP, Guan T, Zhang S. Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2015;9:1963-71. [PMID: 25897206 DOI: 10.2147/DDDT.S75111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
8 Butrous G. The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract 2014;2014:257-90. [PMID: 25780785 DOI: 10.5339/gcsp.2014.42] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]